Tubulis Announces First Patient Dosed in Phase I/IIa Trial Evaluating ADC TUB-030 in Advanced Solid Tumors

CAR-T Digest - August 2020

30 Jan 2025: Tubulis announces first patient dosed in Phase 1/2a trial evaluating ADC TUB-030 in advanced solid tumors

TUB-030 entered clinical evaluation with the first patient dosed in the 5-STAR 1-01 Phase 1/2a trial
It targets 5T4, in solid tumors, developed using Tubulis’ Tubutecan linker-payload platform for precise payload delivery
TUB-030 contains an Fc-silenced IgG1 antibody using Tubulis’ P5 conjugation chemistry and exatecan payload
The trial will enroll 130 patients at sites across the US and Canada. It is evaluating TUB-030 in patients with solid tumors. Phase 1 will be dose escalation, safety, and identifying the MTD and Phase 2a will focus on dose optimization, safety, and preliminary efficacy in selected indications
Preclinical data at AACR showed strong anti-tumor activity, even at low 5T4 expression, with an excellent safety profile
Tubulis now has two differentiated ADCs in clinical trials within a year, reinforcing its position as an innovation driver in ADC development